Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Molibresib versus standard care for AML in first complete remission
ACTRN12619000248167Phase 2Terminated
- Sponsor
- Australasian Leukaemia & Lymphoma Group
- Start
- Jan 2020
- Modality
- Allosteric Modulators → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial in acute myeloid leukemia (AML) comparing Molibresib with Standard of care / observation (2 arms). Primary endpoint: Failure-free survival. Started Jan 2020; status: terminated.
02
Drugs
molibresib
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on ACTRN12619000248167.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12619000248167.